Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia

Osteonecrosis (ON) is a complication of acute lymphoblastic leukaemia (ALL) treatment with patient- (age, female sex, genetic polymorphisms, presence of metabolic syndrome) and treatment-specific (glucocorticoid type and schedule) risk factors described. The potential role of asparaginase in increasing risk of ON via effects on coagulation, lipid metabolism, and steroid clearance is now also recognised. Paediatric studies consistently identify age as a key risk factor for ON, with adolescents at higher risk than young children. Fewer studies comprehensively report on risk of ON in adults, but available evidence suggests that adolescents and young adults (AYAs) treated with corticosteroid and asparaginase-containing paediatric-inspired regimens are more at risk than older adults treated with paediatric-inspired or traditional adult regimens. There are few proven strategies to prevent or mitigate the severity of ON and other orthopaedic complications of ALL therapy. Future clinical trials should carefully ascertain orthopaedic adverse events in adults. Evidence-based guidelines should be developed for management of orthopaedic adverse events in adults being treated for ALL, especially high-risk AYAs being treated with paediatric-inspired regimens.

Automated summary

Osteonecrosis (ON) is a complication of acute lymphoblastic leukaemia (ALL) treatment, with patient and treatment-specific risk factors. Age is consistently identified as a key risk factor, with adolescents at higher risk. Limited studies on adults suggest that adolescents and young adults (AYAs) treated with specific regimens are more at risk. Effective strategies for prevention and management of osteonecrosis and other orthopaedic complications are lacking. Further research and evidence-based guidelines are needed, particularly for high-risk AYAs being treated with paediatric-inspired regimens.